DRAXIS Appoints New President of Contract Manufacturing Unit.Business Editors/Health/Medical Writers MISSISSAUGA, Ontario--(BUSINESS WIRE)--May 8, 2003 DRAXIS Health Inc. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension :DAX) (Nasdaq:DRAX) has appointed Mr. John E.M. Durham as the new President of DRAXIS Pharma Inc. (DPI (Dots Per Inch) The measurement of the resolution of display and printing systems. A typical CRT screen provides 96 dpi, which provides 9,216 dots per square inch (96x96). Flat panel displays from 110 to 200 dpi have also been developed. ), the Company's specialized pharmaceutical contract manufacturing subsidiary in Montreal, Quebec. Mr. Durham will report to Dr. Martin Barkin, President and Chief Executive Officer of DRAXIS Health Inc., and will also serve as a member of the DRAXIS executive management team. "We are very excited to have John join the DRAXIS team," said Dr. Barkin. "Serving the needs of our existing customers and capitalizing on the many opportunities facing DPI will be key drivers for the success of DRAXIS and we are confident that John's extensive experience in pharmaceutical manufacturing will significantly contribute to our steady growth as a specialty pharmaceutical company." Mr. Durham brings to DPI more than 20 years of progressive experience in pharmaceutical production, leading to his most recent position as General Manager for international contract manufacturer Banner Pharmacaps (Canada) Limited, where he had full managerial and financial responsibility for operations, finance, sales & marketing, business development and strategic planning Strategic planning is an organization's process of defining its strategy, or direction, and making decisions on allocating its resources to pursue this strategy, including its capital and people. . Mr. Durham started his pharmaceutical industry career in 1978 and has held increasingly responsible positions spanning all aspects of cGMP-compliant manufacturing for leading pharmaceutical companies including Upjohn, Alcon Laboratories, the McNeil Consumer Healthcare division of Johnson & Johnson and Sandoz Canada. Mr. Durham earned his Bachelor of Science Noun 1. Bachelor of Science - a bachelor's degree in science BS, SB bachelor's degree, baccalaureate - an academic degree conferred on someone who has successfully completed undergraduate studies in microbiology microbiology: see biology. microbiology Scientific study of microorganisms, a diverse group of simple life-forms including protozoans, algae, molds, bacteria, and viruses. from the University of Guelph The University of Guelph is a medium-sized university located in Guelph, Ontario, established in 1964. While the U of G offers degrees in many different disciplines, the university is best known for its focus on life sciences, based in part on a long-standing history of , and has completed executive development programs at Duke University, North Western University and the Banff Centre. Mr. Durham will assume his responsibilities effective June 2, 2003. About DRAXIS Health Inc. DRAXIS Health Inc. is a specialty pharmaceutical company focused on the development, production, marketing and distribution of radiopharmaceuticals (DRAXIMAGE) and the provision of pharmaceutical contract manufacturing services, specializing in liquid and freeze-dried injectables and other sterile sterile /ster·ile/ (ster´il) 1. unable to produce offspring. 2. aseptic. ster·ile adj. 1. Not producing or incapable of producing offspring. 2. products (DRAXIS Pharma). Except for historical information, this news release contains certain forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 as amended, which involve risk and uncertainties that may cause actual results to differ materially from the statements made. Such factors include, but are not limited to, timely regulatory approval of the Company's products, the ability to obtain and enforce effective patents, the establishment and maintenance of new corporate alliances, compliance with appropriate governmental regulations, and other risks detailed from time-to-time in the Company's filings with the US Securities and Exchange Commission and Canadian securities authorities. The Company does not undertake to update such forward-looking statements to reflect new information, later events or developments. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion